This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Markovits, J. Articles by Kohn, K. W. Search for Related Content PubMed PubMed Citation Articles by Markovits, J. Articles by Kohn, K. W.

Topoisomerase II-mediated DNA Breaks and Cytotoxicity in Relation to Cell Proliferation and the Cell Cycle in NIH 3T3 Fibroblasts and L1210 Leukemia Cells

Laboratory of Molecular Pharmacology, Division of Cancer Treatment, National Cancer Institute, NIH, Bethesda, Maryland 20892

The DNA intercalator, 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) and the nonintercalator, etoposide (VP-16) produce topoisomerase II-mediated protein-linked DNA strand breaks. This function of topoisomerase II was investigated in relation to cell proliferation and cell cycle. Mouse fibroblasts NIH 3T3 and mouse leukemia L1210 cells stop proliferation when they reach a certain density. Nuclei were isolated from proliferative or quiescent cells and then treated with drug for 30 min. DNA modifications were assayed by alkaline elution. We found that the frequencies of m-AMSA- or VP-16-induced DNA-protein links were higher in nuclei from exponentially growing than in those from quiescent cells in both the 3T3 and the L1210 lines. Drug-induced protein-associated DNA breaks were also studied as a function of the cell cycle in 3T3 cells that had been arrested by contact inhibition in medium containing 1% calf serum and then stimulated to proliferate by replating at a lower cell density in medium containing 10% serum. In these synchronized cells, a large peak of [³H]thymidine incorporation occurred 18–30 h after replating. The yield of DNA-protein cross-links produced by 30-min drug treatments of nuclei isolated at various times after growth initiation increased concomitantly with the peak of the DNA synthesis. The topoisomerase II activity of nuclear extracts, as measured by kinetoplast DNA decatenation followed a similar pattern. Using colony-forming assays, we also observed that m-AMSA and VP-16 were most cytotoxic in proliferative cells and during DNA synthesis. These results suggest that alkaline elution measurement of m-AMSA- or VP-16-induced protein-linked DNA breaks reflects the association of topoisomerase II with DNA. This association is increased during DNA replication, making the cells more vulnerable to m-AMSA and VP-16 at this time.

¹ Present address: Laboratoire de Pharmacologie Moleculaire, LA 147 CNRS, U 140 INSERM, Institut Gustave Roussy, 94805 Villejuif, France.

² To whom requests for reprints should be addressed, at Laboratory of Molecular Pharmacology, National Cancer Institute, NIH, Building 37, Room 5A19, Bethesda, MD 20892.

Received 8/25/86. Revised 12/19/86. Accepted 1/13/87.

This article has been cited by other articles:

				F. Fala, W. L. Blalock, P. L. Tazzari, A. Cappellini, F. Chiarini, G. Martinelli, A. Tafuri, J. A. McCubrey, L. Cocco, and A. M. Martelli Proapoptotic Activity and Chemosensitizing Effect of the Novel Akt Inhibitor (2S)-1-(1H-Indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan2-amine (A443654) in T-Cell Acute Lymphoblastic Leukemia Mol. Pharmacol., September 1, 2008; 74(3): 884 - 895. [Abstract] [Full Text] [PDF]

				D. W. Stacey, M. Hitomi, and G. Chen Influence of Cell Cycle and Oncogene Activity upon Topoisomerase IIalpha Expression and Drug Toxicity Mol. Cell. Biol., December 15, 2000; 20(24): 9127 - 9137. [Abstract] [Full Text]

				T. G. Gantchev and D. J. Hunting The Ortho-Quinone Metabolite of the Anticancer Drug Etoposide (VP-16) Is a Potent Inhibitor of the Topoisomerase II/DNA Cleavable Complex Mol. Pharmacol., March 1, 1998; 53(3): 422 - 428. [Abstract] [Full Text]

				M. Binaschi, G. Capranico, L. Dal Bo, and F. Zunino Relationship between Lethal Effects and Topoisomerase II-Mediated Double-Stranded DNA Breaks Produced by Anthracyclines with Different Sequence Specificity Mol. Pharmacol., June 1, 1997; 51(6): 1053 - 1059. [Abstract] [Full Text]